Galecto, Inc. (GLTO)

Market Cap	18.98M
Revenue (ttm)	n/a
Net Income (ttm)	-30.83M
Shares Out	27.11M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,044
Open	0.731
Previous Close	0.711
Day's Range	0.700 - 0.740
52-Week Range	0.500 - 3.700
Beta	1.25
Analysts	Hold
Price Target	7.00 (+899.86%)
Earnings Date	Apr 29, 2024

About GLTO

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 29, 2020
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: GLTO

Analyst Forecast

According to 3 analysts, the average rating for GLTO stock is "Hold." The 12-month stock price forecast is $7.0, which is an increase of 899.86% from the latest price.

Price Target

$7.0

(899.86% upside)

Analyst Consensus: Hold